Gyre Therapeutics, Inc. General and Administrative Expense
Gyre Therapeutics, Inc. (GYRE) reported General and Administrative Expense of $7.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-07
- Gyre Therapeutics, Inc. general and administrative expense for the quarter ending 2026-06-30 was $7.87M, a 8.11% increase year-over-year.
- Gyre Therapeutics, Inc. general and administrative expense for the quarter ending 2026-03-31 was $7.22M, a 45.71% increase year-over-year.
- Gyre Therapeutics, Inc. general and administrative expense for the quarter ending 2025-12-31 was $6.70M, a 22.64% increase year-over-year.
- Gyre Therapeutics, Inc. general and administrative expense for the quarter ending 2025-09-30 was $4.32M, a 12.97% increase year-over-year.
- Gyre Therapeutics, Inc. general and administrative expense for fiscal 2025 was $20.80M, a 29.15% increase from fiscal 2024.
- Gyre Therapeutics, Inc. general and administrative expense for fiscal 2024 was $16.11M, a 9.87% increase from fiscal 2023.
- Gyre Therapeutics, Inc. general and administrative expense for fiscal 2023 was $14.66M, a 15.59% decline from fiscal 2022.
- Gyre Therapeutics, Inc. general and administrative expense for fiscal 2022 was $17.37M, a 8.40% decline from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 3 month as first filed | General and Administrative Expense 6 month | General and Administrative Expense 6 month as first filed | General and Administrative Expense 9 month | General and Administrative Expense 9 month as first filed | General and Administrative Expense 12 month | General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.87M 10-Q · filed 2026-08-07 | $18.04M 10-Q · filed 2026-08-07 | $21.79M derived: sum of 3 quarters · filed 2026-08-07 | $26.11M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $7.22M 10-Q · filed 2026-05-08 | $13.92M derived: sum of 2 quarters · filed 2026-05-08 | $18.24M derived: sum of 3 quarters · filed 2026-05-08 | $25.52M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.02M derived: sum of 2 quarters · filed 2026-03-13 | $18.30M derived: sum of 3 quarters · filed 2026-08-07 | $20.80M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $4.32M 10-Q · filed 2025-11-07 | $11.60M derived: sum of 2 quarters · filed 2026-08-07 | $14.10M 10-Q · filed 2025-11-07 | $22.02M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $7.28M 10-Q · filed 2026-08-07 | $4.83M 10-Q · filed 2025-08-11 | $15.48M 10-Q · filed 2026-08-07 | $9.78M 10-Q · filed 2025-08-11 | $17.70M derived: sum of 3 quarters · filed 2026-08-07 | $21.52M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $4.96M 10-Q · filed 2026-05-08 | $10.42M derived: sum of 2 quarters · filed 2026-05-08 | $14.24M derived: sum of 3 quarters · filed 2026-05-08 | $17.67M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $9.29M derived: sum of 2 quarters · filed 2026-03-13 | $12.71M derived: sum of 3 quarters · filed 2026-03-13 | $16.11M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $3.82M 10-Q · filed 2025-11-07 | $7.25M derived: sum of 2 quarters · filed 2025-11-07 | $10.64M 10-Q · filed 2025-11-07 | $20.70M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $3.42M 10-Q · filed 2025-08-11 | $6.82M 10-Q · filed 2025-08-11 | $16.88M derived: sum of 3 quarters · filed 2025-08-11 | $18.03M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-09 | $13.45M derived: sum of 2 quarters · filed 2025-05-09 | $14.61M derived: sum of 3 quarters · filed 2025-05-09 | $16.32M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $11.21M derived: sum of 2 quarters · filed 2025-03-17 | $12.92M derived: sum of 3 quarters · filed 2025-03-17 | $14.66M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $1.16M 10-Q · filed 2024-11-13 | $2.41M 10-Q · filed 2023-10-26 | $2.87M derived: sum of 2 quarters · filed 2024-11-13 | $4.61M 10-Q · filed 2024-11-13 | $8.60M 10-Q · filed 2023-10-26 | $8.78M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $1.71M 10-Q · filed 2024-08-13 | $2.23M 10-Q · filed 2023-08-14 | $3.45M 10-Q · filed 2024-08-13 | $6.20M 10-Q · filed 2023-08-14 | $7.62M derived: sum of 3 quarters · filed 2024-08-13 | $11.98M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-13 | $3.97M 10-Q · filed 2023-05-15 | $5.91M derived: sum of 2 quarters · filed 2024-05-13 | $10.27M derived: sum of 3 quarters · filed 2024-05-13 | $14.12M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $8.53M derived: sum of 2 quarters · filed 2024-03-27 | $12.38M derived: sum of 3 quarters · filed 2024-03-27 | $17.37M 10-K · filed 2024-03-27 | $17.37M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $4.36M 10-Q · filed 2023-10-26 | $8.21M derived: sum of 2 quarters · filed 2023-10-26 | $13.20M 10-Q · filed 2023-10-26 | $17.36M derived: sum of 4 quarters · filed 2023-10-26 | ||||
| 2022-06-30 | $3.84M 10-Q · filed 2023-08-14 | $8.84M 10-Q · filed 2023-08-14 | $13.00M derived: sum of 3 quarters · filed 2023-08-14 | $17.87M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-15 | $9.16M derived: sum of 2 quarters · filed 2023-05-15 | $14.03M derived: sum of 3 quarters · filed 2023-05-15 | $18.55M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.03M derived: sum of 2 quarters · filed 2023-03-30 | $13.55M derived: sum of 3 quarters · filed 2023-03-30 | $18.96M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $4.87M 10-Q · filed 2022-11-14 | $9.39M derived: sum of 2 quarters · filed 2022-11-14 | $14.80M 10-Q · filed 2022-11-14 | $19.08M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $4.52M 10-Q · filed 2022-08-15 | $9.93M 10-Q · filed 2022-08-15 | $14.21M derived: sum of 3 quarters · filed 2022-08-15 | $18.05M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $5.41M 10-Q · filed 2022-05-09 | $9.70M derived: sum of 2 quarters · filed 2022-05-09 | $13.53M derived: sum of 3 quarters · filed 2022-05-09 | $17.90M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $8.12M derived: sum of 2 quarters · filed 2022-03-31 | $12.49M derived: sum of 3 quarters · filed 2022-03-31 | $16.18M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $3.83M 10-Q · filed 2021-11-12 | $8.20M derived: sum of 2 quarters · filed 2021-11-12 | $11.89M 10-Q · filed 2021-11-12 | $15.09M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $4.37M 10-Q · filed 2021-08-05 | $8.06M 10-Q · filed 2021-08-05 | $11.26M derived: sum of 3 quarters · filed 2021-08-05 | $14.52M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $3.69M 10-Q · filed 2021-05-06 | $6.88M derived: sum of 2 quarters · filed 2021-05-06 | $10.15M derived: sum of 3 quarters · filed 2021-05-06 | $13.42M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $6.46M derived: sum of 2 quarters · filed 2021-03-04 | $9.73M derived: sum of 3 quarters · filed 2021-03-04 | $13.42M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $3.27M 10-Q · filed 2020-11-05 | $6.54M derived: sum of 2 quarters · filed 2020-11-05 | $10.22M 10-Q · filed 2020-11-05 | $13.67M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $3.27M 10-Q · filed 2020-08-06 | $6.96M 10-Q · filed 2020-08-06 | $10.40M derived: sum of 3 quarters · filed 2020-08-06 | $13.17M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $3.69M 10-Q · filed 2020-05-11 | $7.13M derived: sum of 2 quarters · filed 2020-05-11 | $9.90M derived: sum of 3 quarters · filed 2020-05-11 | $13.13M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $6.21M derived: sum of 2 quarters · filed 2020-02-20 | $9.44M derived: sum of 3 quarters · filed 2020-02-20 | $12.35M 10-K · filed 2020-02-20 | ||||
| 2018-09-30 | $2.77M 10-Q · filed 2019-11-07 | $6.00M derived: sum of 2 quarters · filed 2019-11-07 | $8.91M 10-Q · filed 2019-11-07 | $11.49M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $3.23M 10-Q · filed 2019-08-01 | $6.14M 10-Q · filed 2019-08-01 | $8.72M derived: sum of 3 quarters · filed 2019-08-01 | $11.12M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $2.91M 10-Q · filed 2019-05-02 | $5.50M derived: sum of 2 quarters · filed 2019-05-02 | $7.89M derived: sum of 3 quarters · filed 2019-05-02 | $10.54M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $4.98M derived: sum of 2 quarters · filed 2019-03-08 | $7.63M derived: sum of 3 quarters · filed 2019-03-08 | $9.99M 10-K · filed 2019-03-08 | ||||
| 2017-09-30 | $2.39M 10-Q · filed 2018-11-01 | $5.04M derived: sum of 2 quarters · filed 2018-11-01 | $7.41M 10-Q · filed 2018-11-01 | $9.61M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $2.65M 10-Q · filed 2018-08-02 | $5.02M 10-Q · filed 2018-08-02 | $7.21M derived: sum of 3 quarters · filed 2018-08-02 | $9.64M derived: sum of 4 quarters · filed 2018-08-02 | ||||
| 2017-03-31 | $2.38M 10-Q · filed 2018-05-03 | $4.56M derived: sum of 2 quarters · filed 2018-05-03 | $6.99M derived: sum of 3 quarters · filed 2018-05-03 | $9.26M derived: sum of 4 quarters · filed 2018-05-03 | ||||
| 2016-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $4.60M derived: sum of 2 quarters · filed 2018-03-19 | $6.88M derived: sum of 3 quarters · filed 2018-03-19 | $9.26M 10-K · filed 2018-03-19 | ||||
| 2016-09-30 | $2.42M 10-Q · filed 2017-11-02 | $4.70M derived: sum of 2 quarters · filed 2017-11-02 | $7.08M 10-Q · filed 2017-11-02 | $10.12M derived: sum of 4 quarters · filed 2017-11-02 | ||||
| 2016-06-30 | $2.27M 10-Q · filed 2017-08-03 | $4.66M 10-Q · filed 2017-08-03 | $7.69M derived: sum of 3 quarters · filed 2017-08-03 | $10.20M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-03-31 | $2.40M 10-Q · filed 2017-05-11 | $5.42M derived: sum of 2 quarters · filed 2017-05-11 | $7.93M derived: sum of 3 quarters · filed 2017-05-11 | $9.67M derived: sum of 4 quarters · filed 2017-05-11 | ||||
| 2015-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $5.54M derived: sum of 2 quarters · filed 2017-03-08 | $7.27M derived: sum of 3 quarters · filed 2017-03-08 | $9.59M 10-K · filed 2017-03-08 | ||||
| 2015-09-30 | $2.51M 10-Q · filed 2016-11-03 | $4.25M derived: sum of 2 quarters · filed 2016-11-03 | $6.57M 10-Q · filed 2016-11-03 | $7.64M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-06-30 | $1.74M 10-Q · filed 2016-08-04 | $2.75M 10-Q · filed 2015-07-31 | $4.06M 10-Q · filed 2016-08-04 | $6.13M 10-Q · filed 2015-07-31 | $5.13M derived: sum of 3 quarters · filed 2016-08-04 | $5.98M derived: sum of 4 quarters · filed 2016-08-04 | ||
| 2015-03-31 | $2.32M 10-Q · filed 2016-05-05 | $3.39M 10-Q · filed 2015-05-07 | $3.40M derived: sum of 2 quarters · filed 2016-05-05 | $4.25M derived: sum of 3 quarters · filed 2016-05-05 | $7.11M derived: sum of 4 quarters · filed 2016-05-05 | |||
| 2014-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $1.92M derived: sum of 2 quarters · filed 2016-03-09 | $4.79M derived: sum of 3 quarters · filed 2016-03-09 | $4.05M 10-K · filed 2016-03-09 | $10.17M 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $849.00K 10-Q · filed 2015-11-05 | $2.36M 10-Q · filed 2014-11-06 | $3.72M derived: sum of 2 quarters · filed 2015-11-05 | $2.98M 10-Q · filed 2015-11-05 | $7.99M 10-Q · filed 2014-11-06 | $1.21M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-06-30 | $1.22M 8-K/A · filed 2015-10-23 | $2.13M 8-K/A · filed 2015-10-23 | $5.63M 10-Q · filed 2014-08-07 | $358.00K derived: sum of 3 quarters · filed 2016-03-09 | $3.19M derived: sum of 4 quarters · filed 2016-03-09 | |||
| 2014-03-31 | $2.76M 10-Q · filed 2015-05-07 | -$2.51M derived: sum of 2 quarters · filed 2016-03-09 | $325.00K derived: sum of 3 quarters · filed 2016-03-09 | $3.36M derived: sum of 4 quarters · filed 2016-03-09 | ||||
| 2013-12-31 | -$5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | -$2.44M derived: sum of 2 quarters · filed 2016-03-09 | $596.00K derived: sum of 3 quarters · filed 2016-03-09 | $4.09M 10-K · filed 2016-03-09 | $12.01M 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $2.83M 10-Q · filed 2014-11-06 | $5.87M derived: sum of 2 quarters · filed 2014-11-06 | $9.36M 10-Q · filed 2014-11-06 | $12.46M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-06-30 | $3.03M 10-Q · filed 2014-08-07 | $6.52M 10-Q · filed 2014-08-07 | $9.63M derived: sum of 3 quarters · filed 2015-03-16 | $12.06M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-03-31 | $3.49M 10-Q · filed 2014-05-08 | $6.59M derived: sum of 2 quarters · filed 2015-03-16 | $9.03M derived: sum of 3 quarters · filed 2015-03-16 | $13.61M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2012-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $5.54M derived: sum of 2 quarters · filed 2015-03-16 | $10.12M derived: sum of 3 quarters · filed 2015-03-16 | $13.19M 10-K · filed 2015-03-16 | ||||
| 2012-09-30 | $2.43M 10-Q · filed 2013-11-06 | $7.02M derived: sum of 2 quarters · filed 2013-11-06 | $10.09M 10-Q · filed 2013-11-06 | $13.11M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-06-30 | $4.59M 10-Q · filed 2013-08-07 | $7.66M 10-Q · filed 2013-08-07 | $10.68M derived: sum of 3 quarters · filed 2014-03-14 | $13.52M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-03-31 | $3.07M 10-Q · filed 2013-05-08 | $6.09M derived: sum of 2 quarters · filed 2014-03-14 | $8.93M derived: sum of 3 quarters · filed 2014-03-14 | $12.06M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $5.86M derived: sum of 2 quarters · filed 2014-03-14 | $8.99M derived: sum of 3 quarters · filed 2014-03-14 | $12.17M 10-K · filed 2014-03-14 | ||||
| 2011-09-30 | $2.84M 10-Q · filed 2012-11-08 | $5.97M derived: sum of 2 quarters · filed 2012-11-08 | $9.15M 10-Q · filed 2012-11-08 | $11.51M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-06-30 | $3.13M 10-Q · filed 2012-08-09 | $6.30M 10-Q · filed 2012-08-09 | $8.67M derived: sum of 3 quarters · filed 2013-03-15 | $10.72M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-03-31 | $3.17M 10-Q · filed 2012-05-09 | $5.54M derived: sum of 2 quarters · filed 2013-03-15 | $7.59M derived: sum of 3 quarters · filed 2013-03-15 | $9.40M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2010-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $4.42M derived: sum of 2 quarters · filed 2013-03-15 | $6.23M derived: sum of 3 quarters · filed 2013-03-15 | $8.05M 10-K · filed 2013-03-15 | ||||
| 2010-09-30 | $2.05M 10-Q · filed 2011-11-03 | $3.87M derived: sum of 2 quarters · filed 2011-11-03 | $5.69M 10-Q · filed 2011-11-03 | |||||
| 2010-06-30 | $1.81M 10-Q · filed 2011-08-09 | $3.64M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $8.17M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |